ProQR Therapeutics (PRQR) EBT (2013 - 2026)
ProQR Therapeutics (PRQR) posted EBT of -$15.7 million for Q1 2026, down 34.29% sequentially from -$11.7 million in Q4 2025, and down 42.54% YoY from -$27.3 million in Q1 2025.
ProQR Therapeutics (PRQR) EBT (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported EBT for 14 years, with the latest figure at -$15.7 million in Q1 2026.
- Quarterly EBT fell 42.54% year-over-year to -$15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.0 million (down 63.77% YoY) and the FY2025 annual result came in at -$50.4 million, down 68.58% from the prior year.
- EBT retreated to -$15.7 million in Q1 2026 per PRQR's latest filing, from -$11.7 million in the prior quarter.
- Over five years, EBT peaked at -$3.1 million in Q2 2024 and troughed at -$23.4 million in Q3 2022.
- A 5-year average of -$11.4 million and a median of -$11.0 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2025: EBT soared 74.62% in 2023, then tumbled 342.01% in 2025.
- Over 5 years, EBT stood at -$13.6 million in 2022, then soared by 46.08% to -$7.3 million in 2023, then tumbled by 35.9% to -$9.9 million in 2024, then dropped by 17.34% to -$11.7 million in 2025, then plunged by 34.29% to -$15.7 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$15.7 million, -$11.7 million, and -$12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -15.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.67 Mn |
| Dec 31, 2025 | -11.67 Mn |
| Sep 30, 2025 | -12.87 Mn |
| Jun 30, 2025 | -13.77 Mn |
| Mar 31, 2025 | -10.99 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -8.90 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Mar 31, 2024 | -8.32 Mn |
| Dec 31, 2023 | -7.32 Mn |
| Sep 30, 2023 | -5.94 Mn |
| Jun 30, 2023 | -8.73 Mn |
| Mar 31, 2023 | -9.50 Mn |
| Dec 31, 2022 | -13.57 Mn |
| Sep 30, 2022 | -23.43 Mn |
| Jun 30, 2022 | -14.37 Mn |
| Mar 31, 2022 | -15.84 Mn |
| Dec 31, 2021 | -20.84 Mn |
| Sep 30, 2021 | -17.73 Mn |
| Jun 30, 2021 | -18.91 Mn |